IOVS Advertisement
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1167/iovs.07-1542 on April 30, 2009
 (Investigative Ophthalmology and Visual Science. 2009;50:4905-4916.)
© 2009 by The Association for Research in Vision and Ophthalmology, Inc.
doi:10.1167/iovs.07-1542
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
iovs.07-1542v1
50/10/4905    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sakurai, K.
Right arrow Articles by Kishi, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sakurai, K.
Right arrow Articles by Kishi, S.

Effect of Intravitreal Injection of High-Dose Bevacizumab in Monkey Eyes

Kenji Sakurai,1 Hideo Akiyama,1 Yukitoshi Shimoda,1 Izumi Yoshida,1 Masahiko Kurabayashi,2 and Shoji Kishi1

1From the Departments of Ophthalmology and 2Medicine and Biological Science, Gunma University School of Medicine, Gunma, Japan.

PURPOSE. To evaluate the ocular complications of intravitreal injection of high dose bevacizumab in monkey eyes.

METHODS. Four healthy monkeys (Macaca fuscata) received an intravitreal injection of either 6.25 or 12.5 mg bevacizumab in the right eye; the left control eye received an intravitreal injection of the same volume of saline. The eyes were examined using slit lamp and funduscopy, optical coherence tomography (OCT), electroretinography (ERG), fundus photography (FP), fluorescein angiography (FA), and indocyanine green angiography (ICGA). The eyes were enucleated 28 days after the intravitreal injection and subjected to light microscopy.

RESULTS. No pathologic changes were observed by FP, FA, ICGA, OCT, and light microscopy in the eyes injected with either of the two bevacizumab doses. ERG showed no toxic change in the eyes that received the 6.25-mg dose. In two eyes that received the 12.5-mg dose, ERG showed no significant difference between the right and left eyes 4 weeks after injection, although there were transient changes in scotopic responses.

CONCLUSIONS. No irreversible toxic effects were observed in monkey eyes receiving an intravitreal injection of high dose bevacizumab.




This article has been cited by other articles:


Home page
 IOVSHome page
Y. Miura, A. Klettner, and J. Roider
VEGF Antagonists Decrease Barrier Function of Retinal Pigment Epithelium In Vitro: Possible Participation of Intracellular Glutathione
Invest. Ophthalmol. Vis. Sci., September 1, 2010; 51(9): 4848 - 4855.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
S. H. Byeon, S. C. Lee, S. H. Choi, H.-K. Lee, J. H. Lee, Y. K. Chu, and O. W. Kwon
Vascular Endothelial Growth Factor as an Autocrine Survival Factor for Retinal Pigment Epithelial Cells under Oxidative Stress via the VEGF-R2/PI3K/Akt
Invest. Ophthalmol. Vis. Sci., February 1, 2010; 51(2): 1190 - 1197.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the Association for Research in Vision and Ophthalmology